Document Detail


Trastuzumab cardio-oncology: lessons learned.
MedLine Citation:
PMID:  20880820     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment with the humanized monoclonal antibody trastuzumab can significantly improve outcomes for patients with early or metastatic HER2-positive breast cancer. In a small proportion of patients, trastuzumab is associated with an increased risk of cardiac dysfunction. Although the mechanisms have yet to be fully established, trastuzumab may block HER2 signaling in cardiomyocytes, which is believed to be important for protecting the cardiomyocytes from stress such as that induced by treatment with anthracyclines. The risk of trastuzumab-associated cardiac dysfunction can be reduced if patients are evaluated thoroughly for risk factors before treatment (e.g., hypertension, low ejection fraction at onset, hyperglycemia, prior congestive heart failure). In addition, cardiac function must be assessed before and during the treatment period. If cardiac dysfunction occurs during treatment, early intervention can expand the possibilities of reinstitution of trastuzumab treatment. The integration of nonanthracycline adjuvant regimens offers opportunities for cardiac-compromised patients.
Authors:
Cynthia Frankel
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical journal of oncology nursing     Volume:  14     ISSN:  1538-067X     ISO Abbreviation:  Clin J Oncol Nurs     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-30     Completed Date:  2011-02-04     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  9705336     Medline TA:  Clin J Oncol Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  630-40     Citation Subset:  N    
Affiliation:
Memorial Cancer Institute, Hollywood, FL, USA. cfrankel@mhs.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / administration & dosage,  adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / administration & dosage,  adverse effects*
Breast Neoplasms / drug therapy*
Clinical Trials as Topic
Female
Heart Diseases / chemically induced*
Humans
Risk Factors
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemotherapy follow-up in older adults: results of a quality-improvement project.
Next Document:  The Breast Surgery Gallery: an educational and counseling tool for people with breast cancer or havi...